Ten insiders at Prelude Therapeutics Inc. (PRLD) reported significant stock purchases totaling approximately $62.50 million on April 23, 2026. Among those acquiring shares were Director and 10% Owner David P. Bonita, along with entities associated with Orbimed, including Genesis GP LLC Orbimed, Capital GP VI LLC Orbimed, Capital LLC Orbimed, and Advisors LLC Orbimed.
Each of these ten insiders purchased shares at a price of $4.44 per share. The transactions involved multiple purchases by each insider, with David P. Bonita and the various Orbimed entities each acquiring approximately 1,689,189 shares for $7.50 million and approximately 1,126,126 shares for $5.00 million in separate transactions.
This cluster of insider buying, with multiple executives and major shareholders increasing their stakes concurrently, is often interpreted as a strong positive signal regarding the company's future prospects by market observers.